Loading
Small Cell Lung Cancer ( SCLC ) / PF-08634404 / Small Cell Lung Cancer · Phase 2 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 registration for a planned trial of PF-08634404 in combination with chemotherapy in adults with transformed small cell lung cancer. No results are reported in this registry record; the study is actively recruiting. The evidence value cannot yet be assessed.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung, Small Cell Cancer Of T…; age from 18 Years. Intervention: PF-08634404. n = 40. 30 sites across 10 countries.
This is a Phase 2 registration for a planned trial of PF-08634404 in combination with chemotherapy in adults with transformed small cell lung cancer. No results are reported in this registry record; the study is actively recruiting. The evidence value cannot yet be assessed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a Phase 2 interventional trial registration with no results yet posted; it describes a planned study design and enrollment target only.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07476287). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 40 participants (ESTIMATED). Conditions: Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung, Small Cell Cancer Of The Lung. Interventions: DRUG: PF-08634404; DRUG: Chemotherapy. Primary outcome measures: Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) , From start of treatment until first documented CR or PR (approximately maximum up to 1 years); Number of Participants with Adverse Events (AEs) , Up to 90 days after the last dose of treatment. Brief summary: This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working. To join the study, participants must meet the following conditions: * Are aged 18 years or older * Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted) * Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs) * Have healthy organs based on medical tests and are in good physical condition After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.